
Shoppers are souring on Lululemon — and chain is getting squeezed by rivals
The pricey retailer known for its $100 leggings has been discounting at 'alarming rates' — even as it has been losing customers to competitors, according to new research from investment bank Jefferies.
At one location ahead of the July 4 weekend, a slim-fit skirt was marked down to $49 from $78 while a pair of jogger pants were marked down to $89 from $128.
5 Lululemon was known for being stingy with discounted apparel, but that's changing now.
SOPA Images/LightRocket via Getty Images
A windproof golf vest was marked down to $79 from $128, according to a July 2 Jefferies report.
The discounting is striking for a retailer that traditionally sold most of its merchandise at full price, Craig Johnson, president of Customer Growth Partners told The Post.
'Historically 95% of their stuff was sold at full price, now they are lucky to get 75% at full price,' Johnson said.
Meanwhile, competitors Vuori and Alo Yoga are going for Lululemon's jugular – and have been gaining market share since February, according several recent Jefferies research reports.
'Alo and Vuori are coming after Lululemon,' Jefferies analyst Randal Konik told The Post.
The privately-held chains are muscling in on Lululemon's turf, opening stores across the street and next door in shopping malls and big cities. On Fifth Avenue in Manhattan, Lululemon's flagship faces an Alo store at the corner of West 48th Street.
Alo, founded in 2007 in Beverly Hills, has 99 stores in the US. San Diego-based Vuori has 93, according to their websites.
5 Alo opened a store across the street from Lululemon on the corner of W. 48th St. and Fifth Avenue.
NYPost/Lisa Fickenscher
Both ramped up their retail expansion over the past few years, according to Konik, and have leaned heavily into social media and influencers. Alo, for one, has bankrolled campaigns with Kendall Jenner, Hailey Bieber and Bella Hadid.
In response, a frantic Lululemon has made a few missteps, including introducing 'loud' colors and sweaters and jackets that customers don't typically associate with the athleisure brand, Konik says.
Bright red, yellow, blue, green and purple merchandise looks more like 'Sesame Street,' Konik laments, and is overwhelming the muted, soft pastels the Vancouver-based chain is known for.
'They are trying to extend the brand to non-athletic people, but these non-core products are on sale,' said Konik, who has maintained an 'underperform rating on Lululemon shares for the past two years.
5 The yoga-gear company has recently added bright red, green, purple and yellow apparel to its assortment.
Getty Images
Lululemon's stock price is down 38% this year, closing at $238 on July 10 and down 54% from its all time high of $516 in December 2023.
At the Lululemon store this week, there were four markdown racks on the third floor filled with bright green, pink, orange and neon yellow, leggings, shorts and jackets. Green leggings were $69, down from $98, and a pair of orange shorts were $49, down from $68. A white windbreaker was $129, marked down from $148.
The Alo store across the street had similarly priced items — but there were no sales racks to be found anywhere in the store.
Over the past several years, Lululemon has opened at least two dozen outlet stores up from just a handful in 2019, according to Johnson.
5 Lululemon is trying to attract non athletic customers, according to Jefferies analyst Randal Konik.
Bloomberg via Getty Images
'The bulk of their highest grossing stores are the outlet locations,' Johnson added.
Lululemon is also leaning into 'logomania,' slapping its name across sweatshirts, jackets and baseball caps – eclipsing its subtle 'Omega' logo that is on every piece of merchandise.
'There's no end to logomania,' Konik writes. Management 'is zeroing in on 'newness' as a panacea for their product struggles…however the outcome is a disjointed assortment that's failing.'
The company did not respond to requests for comment.
In June, it reported that revenues increased by 7% to $2.4 billion in the first quarter ended on May 4, but most of that growth was overseas. Comparable store sales in North America decreased by 2%, the company said.
5 Lululemon has recently added bright colored apparel to its assortment.
Bloomberg via Getty Images
In June, the company said it is laying off 150 corporate employees, according to a Retail Dive report.
It cut its profit forecast for the year in June, blaming outside factors.
'We experienced lower store traffic in the Americas, partially reflective of economic uncertainty, inflationary pressures, lower consumer confidence, and changes in discretionary spending,' Lululemon said in a statement.
In July, it also sued Costco, accusing the massive discounter for ripping off its designs, selling hoodies and pants for $8 and $10 – compared to Lululemon's $118 and $128 price tag for similar products – that look too similar to high end retailer's products.
With 770 stores, Lululemon is still the number one chain among premium athleisure brands, including The Gap's Athleta chain – with 250 stores – and Free People Movement –with 68 stores.
'The brand is still strong and has loyal customers,' Johnson said. 'But they have had some chinks in their armor.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Aptar's First Nasal Pump Made with 52% Bio-based Material* now Available with Haleon's Otrivin® Brand
The Freepod® nasal spray pump, globally used with the Otrivin® brand, is now made from 52% bio-based feedstock CRYSTAL LAKE, Ill., July 29, 2025--(BUSINESS WIRE)--Aptar Pharma, a global leader in drug delivery and active material science solutions and services, is proud to announce that its Freepod® nasal spray pump - one of the delivery systems for Haleon's Otrivin® brand - is now made with mass balance bio-based resins. This is the first Aptar delivery system using such materials to be commercialized globally. The use of more sustainable renewable plastic resources is a meaningful measure to help reduce the use of fossil-based materials in healthcare primary packaging. Reinforcing circularity in pharmaceutical packaging Aptar Pharma's Freepod® spray pump used with Haleon's Otrivin® Nasal Spray is made of 52% ISCC Plus certified bio-based feedstock. The bottle is produced using a mass balance approach equivalent to 100% bio-based content. Together, the pump and bottle components result in an overall circular material content of 60% for the full nasal spray device. ISCC PLUS certified manufacturing and supply chain Aptar Pharma is committed to helping its customers meet their sustainability goals, such as reducing the use of fossil-based materials in packaging. The Freepod® nasal spray components are made from bio-based resins derived from renewable feedstocks like bio-waste and residual oils, using an ISCC PLUS-certified mass balance approach. The Aptar Pharma manufacturing site in Mezzovico, Switzerland, is ISCC PLUS certified, ensuring full traceability of materials throughout the manufacturing process and supply chain. ISCC Plus certification also covers all external suppliers - including injection molding providers, service partners, and warehouses - guaranteeing a fully (ISCC) certified supply chain for the Freepod® components. Partnership for a more sustainable approach The joint sustainability approach between Haleon (formerly GSK Consumer Healthcare) and Aptar Pharma is built on a long-term partnership spanning over 30 years. This collaboration has led to significant achievements, including the Otrivin® Freepod® winning the World Packaging Award in 2019 for its innovative and sustainable design. The use of bio-based or renewable feedstocks for the Otrivin® products with Freepod® technology supports Haleon's goal to reduce virgin petroleum-based plastic use by 10% by 2025** and by a third by 2030, compared to 2022 levels. Aptar Pharma's Freepod® for Otrivin®, available globally, demonstrates Aptar's commitment to sustainability and innovation. Looking ahead, this collaboration is anticipated to extend to Otrivin Nasal Mist, Haleon's latest microdroplet technology, which is being rolled out globally since 2023. "At Aptar, sustainability is not just a responsibility - it's a strategic advantage," commented Gael Touya, President of Aptar Pharma. "The launch of Freepod® Futurity™ reflects our commitment to developing solutions that respond to consumers' increasing demand for more sustainable healthcare delivery technologies. As a trusted partner to Haleon, we are proud to help drive the success of the Otrivin® brand while enabling a shift away from fossil-based materials in primary packaging. Supporting our partners in reaching their environmental goals reinforces our vision of supporting the healthcare industry, from Formulation to patient." With a strong commitment to sustainability, Aptar Pharma continuously strives to reduce its environmental impact and support its partners in achieving their sustainability goals. *ISCC Plus certified bio-based feedstock, mass balance approach.**The end point for the goal delivery period is the end of the 2025 calendar year. About Aptar Pharma Aptar Pharma is part of AptarGroup, Inc. (NYSE:ATR), a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar's innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding. View source version on Contacts Media Contact: Ciara JacksonAptar Pharma+49 151 1951

Business Insider
6 minutes ago
- Business Insider
This pitch deck helped Gradient Labs, a London AI startup, raise a $13 million Series A funding round in one week
Gradient Labs, a London-based AI startup building customer operations AI agents for fintech companies, said it closed a $13 million funding round in one week, Business Insider has learned exclusively. The Series A round was led by Redpoint Ventures, with participation from LocalGlobe, Puzzle Ventures, Liquid 2 Ventures, and Exceptional Capital. Gradient Labs was co-founded in 2023 by Dimitri Masin, Neal Lathia, and Danai Antoniou — all early employees of Monzo, a challenger bank based in London. BI asked Masin, who is CEO, how he was able to close so quickly and what his advice is for other founders who are trying to fundraise. He answered questions via email and also shared his pitch deck. It might look like it happened overnight, but the groundwork was laid months in advance. We'd been building relationships with investors early — sharing updates, listening to feedback, and staying in touch even when we weren't actively fundraising. So when we officially opened the round, we weren't just another cold pitch. We also came in with a strong foundation: the product was live, the traction was real, and the space we're focused on — AI for customer ops in regulated industries — is very specific and very painful. That specificity helped us stand out in a sea of generic AI pitches. And we were prepared: deck, memo, model — everything was ready to go. That made it easy for interested investors to move quickly. There's no silver bullet. A pitch deck can't make up for weak fundamentals. What helped was clarity: We didn't try to tell an overly broad story. We showed exactly why this problem matters, why we're uniquely qualified to solve it, and how the product is already delivering results. And it was delivering: We reached $1 million in annual recurring revenue in just the first 4 months. We also made sure to point out that we weren't riding the AI hype, but we leaned into specifics, such as traction metrics, real use cases, and product performance. Investors could see that we weren't just chasing a trend. We were building something that works today, and has the potential to reshape customer operations in industries that don't tolerate guesswork. Be brutally honest about your fundamentals. Is the product genuinely good? Is your team equipped to win in this space? Will what you're building still matter when the next big model drops? If not, a clever deck won't save you. Also, don't wait to build investor relationships. Start early, even before you need the money. When you finally do raise, it won't feel like a scramble. And finally, know your space inside out. Founder-market fit is what lets you move fast with conviction. I spent years building machine learning systems for fraud at Monzo — that gave me a real advantage in knowing what regulated companies actually need, and how to deliver it safely. That context is hard to fake. Here is Gradient Labs' series A pitch deck:


Newsweek
6 minutes ago
- Newsweek
Warren Buffett Makes Major Sale
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Berkshire Hathaway, the conglomerate led by revered investor Warren Buffett, has sold roughly one-third of its stake in Verisign, a U.S.-based provider of domain name registry services and internet infrastructure. On Monday, Verisign made the announcement that Berkshire will be selling 4.3 million shares on Monday. In a subsequent release, the company said that these would be priced at $285 per share, meaning the transaction will generate over $1.2 billion for Berkshire while reducing its stake from 14.2 to under 10 percent. Why It Matters Berkshire began investing in Verisign in 2012, according to a prospectus submitted by the company with the Securities and Exchange Commission (SEC). Since that time, the company's stock has risen nearly 700 percent, and Berkshire's sale is being touted as yet another example of its CEO's prescient investment skills. What To Know Verisign is a Virginia-based company best known for operating registries for top-level domains like .com and .net. In its most recent earnings results, the firm reported a 5.9-percent increase in revenue to $410 million in the second quarter. Verisign said that Berkshire may sell a further 515,032 shares—worth roughly $150 million at the $285 price point—and that it will receive no proceeds from the sale. The company added that the transaction is intended to reduce Berkshire's stake to under 10 percent, given this threshold "triggers additional regulatory obligations." Berkshire Hathaway chairman and CEO Warren Buffett during an interview in Omaha, Nebraska, on May 7, 2018. Berkshire Hathaway chairman and CEO Warren Buffett during an interview in Omaha, Nebraska, on May 7, 2018. Nati Harnik/AP Photo, File Buffett's company held nearly 13.3 million shares in Verisign as of late March, according to a filing in May with the SEC. Affiliates of Berkshire have been invested in the company since 2012, a year when the stock averaged around $41 and peaked at more than $49. Verisign, which now boasts a market capitalization of $28.6 billion, has since seen its share price rise to close at $305.98 on Monday, meaning the offer price represented a discount of around 7 percent. According to regulatory filings, Berkshire's portfolio comprises a blend including technology companies—primarily Apple—as well as those in the financial services, energy, automotive and food and drink sectors. What People Are Saying Adam Patti, CEO of VistaShares described Berkshire's portfolio as "really well-balanced portfolio chosen" to CNBC in April, and Buffett as "the most successful investor the world has ever seen." What Happens Next? Verisign shares fell sharply in overnight trading following the announcement, but are up nearly 50 percent in the year-to-date. Buffett is set to step down from his role as Berkshire's CEO at the end of the year, and announced that he would be handing over the reins to Greg Abel, vice-chair of non-insurance operations.